Evidence mapPaperPMID 41155155Full record

ArticleInternational journal of molecular sciences2025

Molecular and Histological Characterization of a Novel Hydrogel-Based Strategy for Inducing Experimental Glaucoma in Mice.

Basel Obied, Stephen Richard, Judith Kramarz Dadon, Tal Corina Sela, Noa Geffen, Michal Halperin-Sternfeld, Lihi Adler-Abramovich, Nitza Goldenberg-Cohen, Alon Zahavi

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Multi-Target Neuroprotective Effects of Flavonoid-RichInternational journal of molecular sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Basel ObiedDepartment of Ophthalmology, Bnai-Zion Medical Center, Haifa 339419, Israel.
Stephen RichardThe Krieger Eye Research Laboratory, Ruth and Bruce Rappaport Faculty of Medicine, Technion-Institute of Technology, Haifa 3498838, Israel.ORCID 0000-0002-1064-7997
Judith Kramarz DadonDepartment of Ophthalmology and Eye Research Laboratory, Felsenstein Medical Research Center, Rabin Medical Center, Petach Tikva 4941492, Israel.ORCID 0000-0002-2281-326X
Tal Corina SelaGray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv 6997801, Israel.ORCID 0000-0001-8077-7749
Noa GeffenDepartment of Ophthalmology and Eye Research Laboratory, Felsenstein Medical Research Center, Rabin Medical Center, Petach Tikva 4941492, Israel.
Michal Halperin-SternfeldDepartment of Oral Biology, Goldschleger School of Dental Medicine, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv 6997801, Israel.
Lihi Adler-AbramovichDepartment of Oral Biology, Goldschleger School of Dental Medicine, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv 6997801, Israel.ORCID 0000-0003-3433-0625
Nitza Goldenberg-CohenDepartment of Ophthalmology, Bnai-Zion Medical Center, Haifa 339419, Israel.ORCID 0000-0002-5648-1873
Alon ZahaviDepartment of Ophthalmology and Eye Research Laboratory, Felsenstein Medical Research Center, Rabin Medical Center, Petach Tikva 4941492, Israel.ORCID 0000-0002-9451-5253

Funding

CSRD VA 1
6 · The paper itself

Abstract

Glaucoma is a leading cause of irreversible blindness, and animal models are essential for studying its pathophysiology and testing therapeutic strategies. In this study, a novel hydrogel-based approach was developed and evaluated to induce experimental glaucoma in mice, using composites of hyaluronic acid (HA) and the self-assembling peptide fluorenylmethoxycarbonyl-diphenylalanine (FmocFF). Two formulations with different HA-to-FmocFF ratios were injected either intracamerally or intravitreally in C57BL/6 mice. Intraocular pressure (IOP) was monitored over 21 days, and retinal tissues were analyzed histologically and immunohistochemically. Significant IOP elevation was observed in one hydrogel formulation (Mixture B), yet without detectable retinal ganglion cell loss. A significant reduction in retinal ganglion cell (RGC) density, independent of IOP changes or injection site, was observed in Mixture A. Histological staining confirmed successful delivery and localization of the hydrogel in the anterior chamber, and no evidence of gliosis, microglial activation, or increased apoptosis was revealed by immunostaining. Collectively, these data position the HA-FmocFF hydrogel as a proof-of-concept that advances glaucoma model development, although it does not yet recapitulate the full disease. This model may facilitate future studies of neuroprotection and disease-modifying therapies in glaucoma without confounding inflammatory responses.

Indexed as

GlaucomaHydrogelsAnimalsDisease Models, AnimalHyaluronic AcidIntraocular PressureMaleMiceMice, Inbred C57BLRetinal Ganglion CellsHyaluronic AcidHydrogelsglaucoma modelhyaluronic acidmouse modelretinal ganglion cell lossself-assembling peptide

Identifiers

PMID41155155
PMCPMC12562490

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.